ProSorp BioTech, Inc. is a Delaware corporation operating in the state of Illinois that is dedicated to developing a new generation of biomimetic blood perfusion devices for disease prevention or management.  The lead product will specifically target and remove proteins and compounds that have been abnormally modified with sugar residues, causing them to lose their function and become pro-inflammatory.  These modified proteins, referred to as advanced glycation end products (AGEs) have elevated concentrations in diabetic patients and patients with End Stage Kidney Disease (ESKD) that are undergoing hemodialysis. ProSorp is developing a technology that will safely and effectively remove AGEs from the blood, decreasing inflammation and the progression of disease.  This technology is easily integrated into the current standard of care for the first target patient population, ESKD, and has the potential to save hundreds of thousands of lives, slow disease progression, and drastically reduce health care costs.